Synergistic binding of actinomycin D and echinomycin to DNA mismatch sites and their combined anti-tumour effects
Nucleic Acids Research · 2023
DOI: 10.1093/nar/gkad156 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2023. Verfasst von Roshan Satange und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Genomics and Bioinformatics, National Chung Hsing University, Taichung402, Taiwan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Echinomycin. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Science and Technology, National Chung Hsing University, Chung Shan Medical University.
Abstract (Originalsprache)
Combination cancer chemotherapy is one of the most useful treatment methods to achieve a synergistic effect and reduce the toxicity of dosing with a single drug. Here, we use a combination of two well-established anticancer DNA intercalators, actinomycin D (ActD) and echinomycin (Echi), to screen their binding capabilities with DNA duplexes containing different mismatches embedded within Watson-Crick base-pairs. We have found that combining ActD and Echi preferentially stabilised thymine-related T:T mismatches. The enhanced stability of the DNA duplex–drug complexes is mainly due to the cooperative binding of the two drugs to the mismatch duplex, with many stacking interactions between the two different drug molecules. Since the repair of thymine-related mismatches is less efficient in mismatch repair (MMR)-deficient cancer cells, we have also demonstrated that the combination of ActD and Echi exhibits enhanced synergistic effects against MMR-deficient HCT116 cells and synergy is maintained in a MMR-related MLH1 gene knockdown in SW620 cells. We further accessed the clinical potential of the two-drug combination approach with a xenograft mouse model of a colorectal MMR-deficient cancer, which has resulted in a significant synergistic anti-tumour effect. The current study provides a novel approach for the development of combination chemotherapy for the treatment of cancers related to DNA-mismatches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Genomics and Bioinformatics, National Chung Hsing University, Taichung402, Taiwan.
- Ph.D. Program in Medical Biotechnology, National Chung Hsing University, Taichung402, Taiwan.
- Graduate Institute of Biotechnology, National Chung Hsing University, Taichung402, Taiwan.
- Department of Life Sciences, National Chung Hsing University, Taichung402, Taiwan.
- Division of Chest Medicine, Changhua Christian Hospital, Changhua City, Taiwan.
- Departement of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung402, Taiwan.
ORCID-Profile: Roshan Satange, Stephen Neidle, Ming-Hon Hou
Förderung
- Ministry of Science and Technology
- National Chung Hsing University
- Chung Shan Medical University
Zitieren
APA
Satange, R., Chang, C. C., Li, L. Y., Lin, S. H., Neidle, S., & Hou, M. H. (2023). Synergistic binding of actinomycin D and echinomycin to DNA mismatch sites and their combined anti-tumour effects. Nucleic Acids Research. https://doi.org/10.1093/nar/gkad156
Vancouver
Satange R, Chang CC, Li LY, Lin SH, Neidle S, Hou MH. Synergistic binding of actinomycin D and echinomycin to DNA mismatch sites and their combined anti-tumour effects. Nucleic Acids Research. 2023. doi:10.1093/nar/gkad156
BibTeX
@article{Satange2023,
author = {Satange, Roshan and Chang, Chih-Chun and Li, Long-Yuan and Lin, Sheng-Hao and Neidle, Stephen and Hou, Ming-Hon},
title = {Synergistic binding of actinomycin D and echinomycin to DNA mismatch sites and their combined anti-tumour effects},
journal = {Nucleic Acids Research},
year = {2023},
doi = {10.1093/nar/gkad156}
}
EUVIMED